Value through Innovation27 July 2016

What is a lay summary?

Clinical Study Results

  • BI 831266 - Neoplasms
    Clinical Study Number 1257.1
    Study Indication Neoplasms
    Product BI 831266
    Generic Name BI 831266
    Lab Code
    Clinical Phase I
    Study Title

    An open-label phase I single dose escalation trial of two dosing schedules of BI 831266 administered intravenously over 24 h continuously in patients with advanced solid tumours

    Study Document
    Trial synopsis 1257.1 english